ClinicalTrials.gg
CompletedNCT01169831EPC-ExUpdated Nov 19, 2026Results posted

Regulation of Endothelial Progenitor Cells by Short-Term Exercise

An interventional study of Exercise Training and Exercise Cessation in Aging, Exercise and Cardiovascular Disease, sponsored by Baltimore VA Medical Center. Completed at 1 site in United States. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Primary conditionCardiovascular DiseasesRegistry: Motor ActivityReclassifiedWhy we changed it
Registry
Motor Activity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Cardiovascular Diseases
Why
  1. Motor Activity is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Cardiovascular Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Baltimore VA Medical Center · Not applicable, Interventional, and Other

How we know

Updated Nov 19, 2026Results postedEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
50 Years to 80 Years
Sex
All
01

Study summary

Endothelial Progenitor Cells (EPCs) are circulating cells released from bone marrow which are important for maintaining cardiovascular health. The prevalence of cardiovascular disease in older adults is associated with reduced circulating EPC numbers. Studies have shown reduced EPC number and function in old vs. young individuals, and endurance exercise training increases EPC number and function in young adults. Oxidative stress adversely affects endothelial cells and preliminary evidence indicates that oxidative stress negatively affects EPC function. Conversely, regular exercise reduces markers of oxidative stress and may enhance EPC function in older adults. The investigators hypothesize that older endurance-trained athletes and matched sedentary individuals will have markedly divergent EPC function and that altering the physical activity levels of both groups will move them to intermediate points between these two extremes. The investigators also propose that the investigators can "mimic" the effect of exercise training on EPC function in cell culture by altering intracellular levels of a key enzyme and a signaling molecule which the investigators have shown to regulate EPC function with respect to exercise training in young individuals.

02

Conditions studied

  • Aging
  • Exercise
  • Cardiovascular Disease

Browse trials for

03

In context

Cardiovascular Diseases Reclassified

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's enrollment of 33 is below the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Baltimore VA Medical Center is the lead sponsor of 19 studies on the registry; 2 are open to participants now.

Compared within Cardiovascular Diseases, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Motor Activity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 50-80 years of age, = 18-35 kg/m2, non-smoking, women must be

Exclusion criteria

Exclusion Criteria:

  • history of cardiovascular/cerebrovascular disease, diabetes, cancer, renal, liver disease, ; uncontrolled hyperlipidemia/hypertension
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Sedentary Older Adults

    Other: Exercise Training

  • Experimental
    Older Endurance Athletes

    Other: Exercise Cessation

Interventions

  • OtherExercise Training

    2 weeks of daily aerobic exercise training

  • OtherExercise Cessation

    Stopping all exercise for 2 weeks

06

What researchers measure

Primary outcomes

  1. Baseline Flow-mediated Dilation

    Percent dilation of the brachial artery in response to an increase in blood flow.

    Time frame: Baseline

  2. Final Flow-mediated Dilation

    Percent dilation of the brachial artery in response to an increase in blood flow.

    Time frame: Day 15

Secondary outcomes

  1. Final Endothelial Progenitor Cell Number

    The number of cells in blood samples that expressed both the Cluster of Differentiation 34 protein and the Kinase Insert Domain Receptor protein

    Time frame: Day 15

  2. Baseline Endothelial Progenitor Cell Number

    The number of cells in blood samples that expressed both the Cluster of Differentiation 34 protein and the Kinase Insert Domain Receptor protein

    Time frame: Baseline

07

Results

Posted Nov 19, 2026

Participant flow

Participant flow — Overall Study
MilestoneSedentary Older AdultsOlder Endurance Athletes
Started1419
Completed1217
Not completed22

Outcome measures

PrimaryBaseline Flow-mediated Dilation

Percent dilation of the brachial artery in response to an increase in blood flow.

Time frame:
Baseline
Reported as:
Mean · percent of baseline diameter
Baseline Flow-mediated Dilation
percent of baseline diameterSedentary Older AdultsOlder Endurance Athletes
Baseline Flow-mediated Dilation10.3 ± 4.710.1 ± 5.8
PrimaryFinal Flow-mediated Dilation

Percent dilation of the brachial artery in response to an increase in blood flow.

Time frame:
Day 15
Reported as:
Mean · percent of baseline diameter
Final Flow-mediated Dilation
percent of baseline diameterSedentary Older AdultsOlder Endurance Athletes
Final Flow-mediated Dilation16.2 ± 4.68.8 ± 5.1
SecondaryFinal Endothelial Progenitor Cell Number

The number of cells in blood samples that expressed both the Cluster of Differentiation 34 protein and the Kinase Insert Domain Receptor protein

Time frame:
Day 15
Reported as:
Mean · Cells per 100,000 total cells
Final Endothelial Progenitor Cell Number
Cells per 100,000 total cellsSedentary Older Adults
Final Endothelial Progenitor Cell Number50.7 ± 40.7
SecondaryBaseline Endothelial Progenitor Cell Number

The number of cells in blood samples that expressed both the Cluster of Differentiation 34 protein and the Kinase Insert Domain Receptor protein

Time frame:
Baseline
Reported as:
Mean · Cells per 100,000 total cells
Baseline Endothelial Progenitor Cell Number
Cells per 100,000 total cellsSedentary Older Adults
Baseline Endothelial Progenitor Cell Number24.8 ± 22.6

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sedentary Older Adults—0/14 (0%)0/14 (0%)
Older Endurance Athletes—0/19 (0%)0/19 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sedentary Older AdultsOlder Endurance AthletesTotal
Mean61 ± 862 ± 762 ± 7
Sex: Female, Male
Sex: Female, Male(Participants)Sedentary Older AdultsOlder Endurance AthletesTotal
Female9615
Male51318
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sedentary Older AdultsOlder Endurance AthletesTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American4610
White91120
More than one race011
Unknown or Not Reported000
Flow-mediated dilation
Flow-mediated dilation(Percent of baseline diameter)Sedentary Older AdultsOlder Endurance AthletesTotal
Mean10.3 ± 4.710.1 ± 5.810.2 ± 5.2
08

Study locations

1 site
  • University of Maryland, Baltimore & Baltimore VA Medical Center
    Baltimore, Maryland 21201, United States
09

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Nov 2014 and a completion of Jul 2024. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2026, 12 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2010
First posted
Jul 26, 2010
Start
Jul 2011
Primary completionActual
Nov 2014
CompletionActual
Jul 31, 2024
Results first posted
Nov 19, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 19, 2026
Enrollment
60 (estimated)→33 (actual)
Nov 19, 2026
Primary outcomes
2 added, 2 removed
What changed in the outcomes
  • AddedBaseline Flow-mediated DilationTime frame: Baseline
  • AddedFinal Flow-mediated DilationTime frame: Day 15
  • RemovedBaseline Endothelial progenitor cell numberTime frame: Day 1
  • RemovedFinal Endothelial Progenitor Cell NumberTime frame: Day 15
Nov 19, 2026
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedBaseline Endothelial ReactivityProgenitor Cell NumberTime frame: Day 1 → Baseline
  • EditedFinal Endothelial ReactivityProgenitor Cell NumberTime frame: Day 15
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Results posted
    Enrollment 60 (estimated)→33 (actual)
    Primary outcomes 2 added, 2 removed
    What changed in the outcomes
    • AddedBaseline Flow-mediated DilationTime frame: Baseline
    • AddedFinal Flow-mediated DilationTime frame: Day 15
    • RemovedBaseline Endothelial progenitor cell numberTime frame: Day 1
    • RemovedFinal Endothelial Progenitor Cell NumberTime frame: Day 15
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedBaseline Endothelial ReactivityProgenitor Cell NumberTime frame: Day 1 → Baseline
    • EditedFinal Endothelial ReactivityProgenitor Cell NumberTime frame: Day 15
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01169831
Lead sponsor
Baltimore VA Medical Center
Collaborators
University of Maryland, Baltimore, University of Maryland, College Park
Responsible party
Steven J. Prior, Ph.D. (Assistant Professor, University of Maryland, Baltimore) — Principal investigator
First posted
Jul 26, 2010
Start date
Jul 2011
Primary completion
Nov 2014
Completion
Jul 31, 2024
Results posted
Nov 19, 2026
Last update
Nov 19, 2026

Study contacts

Steven J Prior, Ph.D.
principal investigator · University of Maryland, Baltimore

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion